

## Index

### a

absorption, distribution, metabolism, excretion and toxicity (ADMET) 16, 23, 278  
 action potential duration (APD) 58  
 adrenergic receptors 30  
 $\alpha$ 1-adrenergic receptors ( $\alpha$ 1-ARs) 130, 156  
 adrenocorticotrophic hormone (ACTH) 304  
 adverse drug reactions (ADRs) 3, 23  
 affinity fingerprint method 25  
 alanine-scanning mutagenesis 59  
 amineptine 4, 5  
 aminophenazone 5  
 aminosteroid 9  
 artificial neural networks analysis 464  
 aryl hydrocarbon receptor (AhR) 199, 330  
 astemizole 5  
 atorvastatin acid 345  
 ATP-binding cassette (ABC) 341, 367  
 – efflux transporters 351  
 azidothymidine monophosphate (AZT) 348

### b

Ballosteros–Weinstein nomenclature 135  
 bilinear regression models 177  
 bilirubin glucuronides 348  
 biogenic amine-binding GPCRs 182  
 BioPrint biological fingerprints 23, 25, 28, 36, 39, 41  
 blood–brain barrier (BBB) 350, 471  
 breast cancer resistance protein (BCRP) family 341  
 bromfenac sodium 6

### c

calcium channel blockers 43  
 calcium-gated potassium channel Mth K 90  
 cardiovascular toxicity 11  
 catecholamine neurotransmitters 156  
 cerivastatin 6, 346

chemical reactivity 249

Cheng–Prusoff equation 213

*meta*-chlorophenylpiperazine (mCPP) 149

chlormezanone 6

cholesteryl ester transfer protein (CETP) 14

chronic hypoxia 147

CODESSA method 115

comparative molecular field analysis (CoMFA) 464

comparative structural connectivity spectral analysis (CoSoCoSA) 330

congestive heart failure (CHF) 7

constitutive androstane receptor (CAR) 325  
 – endogenous CAR ligands 325

Crigler–Najjar (CN) syndrome 296, 303

cross-chemotype pharmacophore 130, 183

cyclooxygenase (COX)-2 inhibitor 10

CYP (cytochrome P450) enzymes 277

– CYP2C5 255

– catalyzed reactions 268

– crystal structures 253, 258

– CYP2D6-mediated metabolic pathways 201

– induction 318

– iron-containing porphyrin system 247

– irreversible inhibition 217, 268, 269, 279

– ligand interactions 277

– mechanism-based inhibition 270, 271

– mechanism-based inhibitor (MBI) 218, 220,

222, 225, 267, 285

– membrane-attached cytochrome P450 enzymes 277

– metabolite-based inhibition (MBI) 278

– metabolism prediction 289

– reversible inhibition 203, 221

### d

dexamethasone (DEX) 304

dexfenfluramine 7

divalent bile salts 348

- DNA-binding domain (DBD) 319  
dopaminergic receptors 157, 457  
drug–drug interactions 267, 269, 300, 317, 318  
– quantitative prediction of 269  
drug–hormone interactions 303  
drug metabolism 197, 247  
– drug-metabolizing enzymes 198, 201, 295  
– drug-metabolizing transporters 295  
drug transporter regulation 298, 389  
– computational models for 389  
Dubin–Johnson syndrome 298, 303, 348
- e**  
efflux transporters 341  
electrophiles 267  
electrotopological state (ES) values 382  
epinephrine 156  
epirubicin 281  
erythema nodosum leprosum (ENL) 17  
European Agency for the Evaluation of Medicinal Products (EMA) 7
- f**  
farnesoid X receptor (FXR) 297, 326  
fatty acid binding protein (FABP) 307  
fatty acid elongase (FAE) 304  
fatty acid synthase (FAS) 304  
fenfluramine 7  
fexofenadine 94, 127  
fialuridine 12  
fibroblast activation protein (FAP) 404  
fingerprints for ligands and proteins (FLAP) method 287  
flosequinan 7  
Food and Drug Administration (FDA) 3
- g**  
gain-of-function mutation 96  
Genetic Algorithm Similarity Program (GASP) 380  
Gilbert’s disease 303  
glafenine 7, 8  
glucose-dependent insulinotropic polypeptide (GIP) 401  
glucuronic acid conjugation 284  
GLUE program 259  
glutathione S-transferase (GST) 296, 322  
G-protein-coupled receptors (GPCRs) 23, 29, 127, 154, 461  
– antitarget affinity 130  
– antitarget modeling 127  
– heterodimerization 157  
– ligands 157  
Gram-negative pathogens  
– pulmonary infections 10  
grepafloxacin 8  
GRID flexible molecular interaction fields (GRID-MIFs) 282  
GRIND technology 284  
GST regulation 297
- h**  
Hansch approach 159, 169  
hepatic failure 13  
hepatotoxicity 5  
heterocyclic aromatic amines (HAAs) 199  
HIV-protease inhibitor 351  
HMG-CoA reductase inhibitor 6, 345  
hormone response elements (HREs) 293  
human ether-a-go-go-related gene (hERG) channel 16, 89, 90, 91, 93, 109, 119  
– activation gating 95  
– binding site 100  
– blocking drugs 109, 111, 113  
– C-type inactivation gating 93  
– drug-binding site of 95  
– homology model 119, 120  
– ligand-derived models 119  
– mutations in 93  
– neuroendocrine glands 89  
– smooth muscle 93  
– target versus antitarget 56  
– voltage-sensing domain 92  
human liver microsomes (HLMs) 206  
human UDP-glucuronosyl transferases, *see* phase II conjugative metabolism enzymes  
hydrophilic metabolites 277  
hyperbilirubinemia II, *see* Dubin–Johnson syndrome  
hypersensitivity reaction 269  
hypothalamus–pituitary–adrenal (HPA) axis 304
- i**  
immunomodulatory drugs 17  
International Conference on Harmonization (ICH) 66  
*in vitro*–*in vivo* relationships 23
- k**  
KcsA channel X-ray structure 431  
Kohonen self-organizing maps 118, 383
- l**  
lactic acidosis 13  
LC/MS techniques 205  
levacetylmethadol 8

- liberation–absorption–distribution–metabolism–excretion (LADME) 15  
 ligand-binding domain (LBD) 319  
 linear interaction energy (LIE) method 120  
 Lineweaver–Burk visualizations 213–214  
 lithocholic acid (LCA) 302  
 liver X receptors (LXRs) 297, 326, 328  
 low-density lipoprotein (LDL) 6, 14  
 luminogenic assays 205
- m**
- machine learning 324  
 major depressive disorder (MDD) 459  
 mass spectrometry 205, 227  
*mdr1* knockout mouse model 349  
 metabolic biotransformations 277  
 MetaSite 252, 259, 282, 290  
 mibefradil 9  
 Michaelis–Menten kinetic 206, 318  
 mitogen-activated protein kinase (MAPK) 145  
 molecular dynamics (MD) simulations 120  
 molecular interaction fields (MIFs) 383  
 Monte Carlo conformational analysis 180  
 multidimensional optimization paradigm 459  
 multidrug resistance protein (MRP) 298, 341, 346  
 multidrug resistance protein 1 (*Mdr1*) 298  
 – resistant transporter 1 (MDR1) 322–323  
 multilinear regression models 169  
 multiple copies simultaneous search (MCSS) 182  
 muscarinic acetylcholine receptors 30
- n**
- neural network 116, 127, 171  
 neuropsychotic disorders 5  
 neurotransmitter receptors 29  
 new chemical entities (NCEs) 3, 197  
 nonsteroidal anti-inflammatory drug (NSAID) 6  
 norfenfluramine 149  
 N-terminal DNA binding domain (DBD) 293  
 nuclear hormone receptors (NHRs) 23  
 nuclear receptors  
 – activation of 319  
 nucleotide binding domain (NBD) 346, 368
- o**
- organic anion transporting polypeptide (OATP) 298, 341, 342, 390  
 organic anion transporting polypeptide 2 (OATP2) 323
- organic cation transporter family (OCT) 341, 389  
 oxidative biotransformations 284
- p**
- Parkinson's disease 129  
 partial least squares (PLS) 383  
 – regression-based models 324  
 – partial least squares discriminant (PLSD) 384  
 Passe–Partout model 184  
 peripheral blood mononuclear cells (PBMCs) 352  
 P-glycoprotein (P-gp), *see* ATP-binding cassette  
 – crystal structure 371  
 – role of 349  
 – *in vitro* models 369  
 – pharmacophore-based descriptors 40  
 – receptor-based 158  
 pharmacophore models 132, 135  
 phase II conjugative metabolism enzymes 277  
 phase II conjugation reactions 281  
 phenobarbital response element (PBRE) 299  
 polycyclic aromatic hydrocarbons (PAHs) 199  
 polypharmacology  
 – BioPrint analysis 26  
 – of drugs 26  
 pore-forming  $\alpha$ -subunit 89  
 potassium channels 89  
 potential ADR liabilities 49  
 PREDICT technology 433  
 pregnane-activated receptor (PAR) 293  
 pregnane X receptor (PXR) 202, 322  
 – characterization of 293  
 – in lipid metabolism 304  
 – in phase II enzyme regulation 296  
 Protein Data Bank 255, 256  
 protein–protein interactions 157, 208  
 pseudo-Cushing's syndrome 304  
 pseudoxanthoma elasticum (PXE) 349  
 pulmonary hypertension 143
- q**
- QT prolongation 60, 65  
 – dose–response relationship for 67  
 – long QT syndrome (LQTS) 93, 94, 109  
 – drug-induced long QT syndrome 58, 94  
 – regulatory aspects of 66  
 – QT-prolonging drugs 56, 94  
 quantitative structure–activity relationship (QSAR) 100, 156, 159, 170, 171, 323, 382, 391  
 – supermolecule-based QSAR 172

- quantitative structure–property relationship (QSPR) 161
- quantum chemistry 252
- r**
- rapacuronium bromide 9
- reactive metabolites, *see* electrophiles
- receiver operating characteristic (ROC) 122
- receptor-based 158
- receptorome screening 143, 144
- receptor theory 155
- recursive partitioning (RP) 116
- retinoic acid receptor (RAR) 328
- retinoid X receptor (RXR) 202, 293
- rhodopsin-based models 182
- right ventricular systolic pressure (RVSP) 147
- rofecoxib 10
- s**
- Sammon nonlinear maps 118
- seasonal rhinitis 127
- selective serotonin reuptake inhibitors (SSRIs) 458
- serotonin noradrenaline reuptake inhibitors (SNRIs) 458
- short QT syndrome (SQTS) 94
- sick sinus syndrome 9
- single nucleotide polymorphism (SNP) 147
- small cell lung cancer (SCLC) 347
- stearoyl CoA desaturase-1 (SCD-1) 304
- steroid and xenobiotic receptor (SXR) 202, 293
- sterol regulatory element binding protein 1c (SREBP-1c) 304
- Stevens–Johnson syndrome 7
- structure–activity relationships (SAR) 110, 327, 457
- structure-based descriptors 23
- structure-based molecular design approaches 457, 460
- structure–property relationship (SPR) studies 372
- succinylcholine 9
- support vector machine (SVM) 115, 116
- System for Thalidomide Education and Prescribing Safety (STEPS) 17
- t**
- temafloxacin 10
- terfenadine 127
- thalidomide
- revival of 17
- prospective randomized flosequinan longevity evaluation (PROFILE) 7
- thymidine kinase promoter 299
- time-dependent inhibition (TDI) 221
- topology-based methods 118
- torcetrapib 14
- total molecular surface area (TMSA) 166
- traditional Chinese medicines (TCMs) 301
- transporter-mediated drug disposition 342
- troglitazone 10
- u**
- UDP-glucuronosyltransferases (UGTs) 296, 322
- UGT–drug recognition 277
- UGT-mediated glucuronidation 281
- uridine-5-diphosphate- $\alpha$ -d-glucuronic acid (UDPGA) 284
- UV–Vis spectroscopy 274
- v**
- vacuum cleaner model 368
- valvular heart disease (VHD) 143
- van der Waals energy parameters 121
- van der Waals surface area 379
- Van de Water’s formula 71
- vectorial drug transport 352
- venous thromboembolism (VTE) 11
- ventricular action potential 89
- ventricular arrhythmia 109
- ventricular cardiac action potential 91
- VHD-associated drugs 145, 148, 149
- vitamin D receptor (VDR) 326
- voltage-gated channels 90, 95
- voltage-gated potassium channels 89
- w**
- warfarin therapy 200
- x**
- xenobiotic biotransformation processes 198
- xenobiotic receptor 302
- xenobiotic response elements (XREs) 295
- xenobiotics 197
- ximelagatran 11
- X-ray crystallography 120, 282, 371
- z**
- zwitterion approach 425, 434